Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that reduces stomach acid production.
## Primary Indications
* Gastroesophageal reflux disease (GERD) symptom relief and healing of erosive esophagitis.
* Healing of duodenal ulcers.
* *Helicobacter pylori* eradication (in combination with antibiotics).
* Pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome).
## Adult Dosing
* **GERD/Erosive Esophagitis:** 40 mg orally or IV once daily. Dosing may be increased to 40 mg twice daily for short-term use.
* **Duodenal Ulcers:** 40 mg orally once daily for up to 4 weeks.
* ***H. pylori* Eradication:** 40 mg orally twice daily (with amoxicillin 1000 mg twice daily and clarithromycin 500 mg twice daily) for 7-14 days.
* **Pathological Hypersecretory Conditions:** Starting dose typically 40 mg orally or IV twice daily. Doses adjusted based on gastric acid output. Maximum dose: 240 mg daily.
## Pediatric Dosing
* **GERD/Erosive Esophagitis:**
* **1 to <5 years:** 10 mg orally once daily for up to 8 weeks.
* **5 to <12 years:** 20 mg orally once daily for up to 8 weeks.
* **12 years and older:** 40 mg orally once daily for up to 8 weeks.
* IV dosing is available for patients 5 years and older, typically 1.0-1.5 mg/kg/day IV, maximum 40 mg/day. Consult specific institutional protocols for IV administration in pediatrics.
## Dose Adjustments
* **Hepatic Impairment:** Maximum dose of 40 mg orally once daily. No dose adjustment is needed for IV administration in moderate to severe hepatic impairment.
* **Renal Impairment:** No dose adjustment is typically required.
## Contraindications
* Known hypersensitivity to pantoprazole or any component of the formulation.
## Adverse Effects
Common: Diarrhea, headache, nausea, dizziness, abdominal pain.
Long-term use concerns: Increased risk of *Clostridium difficile*-associated diarrhea, bone fractures (hip, wrist, spine), hypomagnesemia, vitamin B12 deficiency.
## Key Drug Interactions
* **Drugs requiring gastric acid for absorption:** Ketoconazole, itraconazole, posaconazole, iron salts, certain antiretrovirals (e.g., rilpivirine, atazanavir). Pantoprazole can decrease their absorption.
* **Methotrexate:** PPIs may increase methotrexate levels.
* **CYP2C19 substrates:** Pantoprazole is a moderate inhibitor of CYP2C19. May affect metabolism of drugs like clopidogrel (though clinical significance is debated).
## Monitoring
* Monitor for signs and symptoms of hypomagnesemia (e.g., muscle cramps, seizures, tremors, arrhythmias) especially with prolonged use (>3 months).
* Monitor for potential bone fracture risk with long-term therapy.
* Monitor for signs of *C. difficile*-associated diarrhea.
## Clinical Pearls
* Administer oral pantoprazole 30-60 minutes before a meal.
* Delayed-release tablets and capsules should be swallowed whole and not chewed or crushed.
* IV formulation may be used when oral route is not feasible.
* Consider the risks associated with long-term PPI use; use the lowest effective dose for the shortest duration necessary.
***
**Disclaimer:** This information is intended for healthcare professionals. Always consult the most current prescribing information and institutional protocols before making treatment decisions.
